Q1 Earnings Estimate for Immunovant Issued By Zacks Research

Immunovant, Inc. (NASDAQ:IMVT) – Stock analysts at Zacks Research reduced their Q1 2026 earnings per share estimates for shares of Immunovant in a report issued on Tuesday, January 7th. Zacks Research analyst E. Bagri now anticipates that the company will post earnings of ($0.82) per share for the quarter, down from their previous estimate of ($0.79). The consensus estimate for Immunovant’s current full-year earnings is ($2.73) per share. Zacks Research also issued estimates for Immunovant’s Q2 2026 earnings at ($0.87) EPS, Q3 2026 earnings at ($0.83) EPS, Q4 2026 earnings at ($0.85) EPS, FY2026 earnings at ($3.38) EPS, Q1 2027 earnings at ($0.87) EPS, Q2 2027 earnings at ($0.95) EPS, Q3 2027 earnings at ($0.90) EPS and FY2027 earnings at ($3.63) EPS.

Immunovant (NASDAQ:IMVT) last issued its quarterly earnings results on Thursday, November 7th. The company reported ($0.74) EPS for the quarter, missing the consensus estimate of ($0.59) by ($0.15). During the same quarter last year, the firm posted ($0.45) EPS.

A number of other research analysts also recently weighed in on IMVT. Wolfe Research downgraded Immunovant from an “outperform” rating to a “peer perform” rating in a report on Friday, January 3rd. Wells Fargo & Company dropped their price objective on shares of Immunovant from $47.00 to $45.00 and set an “overweight” rating on the stock in a research note on Thursday, December 19th. HC Wainwright reaffirmed a “buy” rating and issued a $51.00 price target on shares of Immunovant in a report on Friday, November 8th. Oppenheimer upped their target price on Immunovant from $47.00 to $53.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 9th. Finally, Raymond James reiterated an “outperform” rating and issued a $36.00 price target on shares of Immunovant in a research report on Thursday, October 10th. One research analyst has rated the stock with a hold rating and nine have given a buy rating to the stock. According to data from MarketBeat, Immunovant presently has a consensus rating of “Moderate Buy” and a consensus target price of $47.22.

Immunovant Trading Down 0.6 %

IMVT stock opened at $23.48 on Friday. Immunovant has a 1-year low of $23.08 and a 1-year high of $43.92. The firm has a market capitalization of $3.45 billion, a PE ratio of -10.58 and a beta of 0.66. The business’s 50 day simple moving average is $27.07 and its 200 day simple moving average is $28.58.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the company. FMR LLC increased its holdings in shares of Immunovant by 19.6% in the third quarter. FMR LLC now owns 12,537,571 shares of the company’s stock valued at $357,446,000 after buying an additional 2,053,688 shares in the last quarter. Armistice Capital LLC increased its position in Immunovant by 57.0% in the second quarter. Armistice Capital LLC now owns 3,396,909 shares of the company’s stock worth $89,678,000 after purchasing an additional 1,232,909 shares during the period. State Street Corp boosted its holdings in Immunovant by 11.2% during the third quarter. State Street Corp now owns 3,022,342 shares of the company’s stock worth $86,167,000 after buying an additional 303,386 shares during the last quarter. Geode Capital Management LLC raised its position in shares of Immunovant by 6.9% during the third quarter. Geode Capital Management LLC now owns 1,510,926 shares of the company’s stock worth $43,085,000 after purchasing an additional 96,924 shares during the period. Finally, Baker BROS. Advisors LP increased its position in shares of Immunovant by 163.7% in the third quarter. Baker BROS. Advisors LP now owns 1,225,410 shares of the company’s stock valued at $34,936,000 after acquiring an additional 760,692 shares during the last quarter. 47.08% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, insider Mark S. Levine sold 4,361 shares of Immunovant stock in a transaction dated Wednesday, October 23rd. The stock was sold at an average price of $29.53, for a total value of $128,780.33. Following the completion of the transaction, the insider now owns 322,878 shares in the company, valued at approximately $9,534,587.34. This trade represents a 1.33 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CFO Eva Renee Barnett sold 4,105 shares of the firm’s stock in a transaction on Wednesday, January 8th. The stock was sold at an average price of $24.10, for a total transaction of $98,930.50. Following the completion of the sale, the chief financial officer now owns 327,064 shares of the company’s stock, valued at $7,882,242.40. This trade represents a 1.24 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 77,247 shares of company stock worth $2,034,425 in the last three months. Corporate insiders own 5.90% of the company’s stock.

Immunovant Company Profile

Immunovant, Inc, a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia.